严格筛查策略显著降低结核流行区接受抗TNF治疗的炎症性肠病患者结核再激活率
在结核流行区,炎症性肠病患者接受抗TNF治疗时结核再激活风险高。研究采用双向性队列比较,2019年1月后接受严格筛查(病史、胸片、胸部CT、IGRA、TST,阳性者给予化学预防)的晚期队列与2005年1月至2019年1月的早期队列相比,晚期队列结核再激活率仅1.7%,显著低于早期队列的17%(p<0.01),校正混杂因素后早期队列结核再激活风险显著高于晚期队列(HR 14.52,95%CI 1.90-110.61,p=0.01)。
要点
- 严格筛查策略包括结核病史/接触史、胸片、胸部CT、IGRA、TST,任一阳性即给予化学预防。
- 校正混杂因素后,早期队列结核再激活风险显著高于晚期队列(HR 14.52,95%CI 1.90-110.61,p=0.01)。
核心结论
- 在结核流行区,严格潜伏性结核筛查和化学预防可显著降低接受抗TNF治疗的炎症性肠病患者的结核再激活风险。
研究设计与样本
- 研究为双向性队列比较,纳入171例接受抗TNF治疗的炎症性肠病患者(63例溃疡性结肠炎,108例克罗恩病),中位年龄28.5±13.4岁,男性占60%,抗TNF治疗后中位随访33个月(四分位距23-57个月)。
主要发现
- 早期队列112例中,29例(26%)完成完整结核筛查,22例(19.6%)有潜伏性结核,10例(9%)接受化学预防,19例(17%)发生结核。
- 生存分析显示,校正性别、抗TNF起始年龄、合并免疫抑制、抗TNF剂量和升级治疗后,早期队列结核再激活概率显著高于晚期队列(HR 14.52,95%CI 1.90-110.61,p=0.01)。
关键数值与推荐
- 晚期队列严格筛查标准包括:既往结核病史/近期活动性结核接触史、胸部X线、胸部CT、IGRA、TST,任一阳性即给予化学预防。
- 校正后早期队列相比晚期队列结核再激活风险HR为14.52(95%CI 1.90-110.61,p=0.01)。
临床怎么用
- 作者认为,在结核流行区接受抗TNF治疗的炎症性肠病患者,通过严格潜伏性结核筛查和化学预防可显著降低结核再激活风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-tumor necrosis factor (anti-TNF) therapy use in patients with inflammatory bowel disease (IBD) leads to an increased risk of tuberculosis (TB) reactivation despite latent tuberculosis (LTB) screening, especially in TB endemic regions. AIM: We evaluated the effect of stringent screening strategy and LTB prophylaxis on TB reactivation. METHODS: We performed an ambispective comparison between patients who received anti-TNF therapy after January 2019 (late cohort) and between Jan 2005 and Jan 2019 (early cohort). Late cohort patients were subjected to stringent screening criteria which included all: history of past TB/recent contact with active TB, chest X-ray, CT (computed tomography) chest, IGRA (interferon-gamma release assay), TST (tuberculin skin test), and if any positive were given chemoprophylaxis. A cohort comparison was done to evaluate for risk reduction of TB following the stringent screening strategy. RESULTS: One hundred seventy-one patients (63: ulcerative colitis/108: Crohn's disease, mean age diagnosis: 28.5 ± 13.4 years, 60% males, median follow-up duration after anti-TNF: 33 months [interquartile range: 23-57 months]) were included. Among the 112 in the early cohort, 29 (26%) underwent complete TB screening, 22 (19.6%) had LTB, 10 (9%) received chemoprophylaxis, and 19 (17%) developed TB. In comparison, in the late cohort, 100% of patients underwent complete TB screening, 26 (44%) had LTB, 23 (39%) received chemoprophylaxis, and only 1(1.7%) developed TB (p < 0.01). On survival analysis, patients in early cohort had a higher probability of TB reactivation compared with the late cohort (HR: 14.52 (95% CI: 1.90-110.61 [p = 0.01]) after adjusting for gender, age at anti-TNF initiation, concomitant immunosuppression, anti-TNF doses, and therapy escalation. CONCLUSION: The high risk of TB reactivation with anti-TNF therapy in TB endemic regions can be significantly mitigated with stringent LTB screening and chemoprophylaxis.
引用
- Kumar P, Vuyyuru SK, Kante B, et al. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther. 2022. PMID: 35229906. doi:10.1111/apt.16839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。